Showing 1681-1690 of 1922 results for "".
- Aldeyra Plans to Resubmit New Drug Application for Reproxalap in Dry Eye Diseasehttps://modernod.com/news/aldeyra-plans-to-resubmit-new-drug-application-for-reproxalap-in-dry-eye-disease/2482193/About 4 months after receiving a complete response letter (CRL) from the FDA, Aldeyra Therapeutics announced a clinical development plan intended to enable resubmission of a new drug application (NDA) of topical ocular 0.25% reproxalap, an investigational RASP modulator, for the treatment of dry
- Study: Racial Disparities in Glaucoma Care Persist, Regardless of Socioeconomic Statushttps://modernod.com/news/study-racial-disparities-in-glaucoma-care-persist-regardless-of-socioeconomic-status/2481961/Many studies have shown that glaucoma is more common and more severe in Black and Hispanics than in Whites, but less is known about the impact of racial differences and socioeconomic status on vision loss and individual utilization of health care resources among glaucoma patients, according
- Study of Sickle Retinopathy in Children Shows Similar Rate of Occurence as Adultshttps://modernod.com/news/study-of-sickle-retinopathy-in-children-shows-similar-rate-of-occurence-as-adults/2481945/The American Academy of Ophthalmology (AAO) announced the presentations of a study of sickle retinopathy, an age-dependent process that can develop in patients with sickle cell disease, of whom older patients are at substantially higher risk than younger patients. To learn more about ho
- Aviceda Announces its Glycomimetic Nanoparticle Candidate AVD-104 Demonstrates Clinical Safety in the Treatment of GAhttps://modernod.com/news/aviceda-announces-its-glycomimetic-nanoparticle-candidate-avd-104-demonstrates-clinical-safety-in-the-treatment-of-ga/2481886/Aviceda Therapeutics announced the recent presentation of positive data about AVD-104, its lead ophthalmic clinical asset, at the Euretina congress held in Amsterdam. The phase 2/3 SIGLEC trial is currently underway evaluating patients with geographic atrophy secondary to age-
- Apellis Announces Corporate Restructuring and Workforce Reductionhttps://modernod.com/news/apellis-announces-corporate-restructuring-and-workforce-reduction/2481797/Apellis Pharmaceuticals announced a corporate restructuring that it says will cut costs and position the company for long-term success. As part of the restructuring, Apellis said it is reducing headcount by approximately 225 employees, or about 25% of the current wo
- Johnson & Johnson Vision’s Acuvue Abiliti Brand Launches Back-to-School Campaign to Address Myopiahttps://modernod.com/news/johnson-johnson-visions-acuvue-abiliti-brand-launches-back-to-school-campaign-to-address-myopia/2481762/Johnson & Johnson Vision, part of Johnson & Johnson MedTech, announced that its Acuvue Abiliti brand is initiating a Back-to-School campaign to inform parents about the growing risk of myopia and encourage them to schedule a comprehensive eye exam for their children ahead of the new schoo
- Novel Imaging Technology Reveals Role of Immune Cells in Early Diabetic Cataract Developmenthttps://modernod.com/news/novel-imaging-technology-reveals-role-of-immune-cells-in-early-diabetic-cataract-development-1/2481623/Novel findings from researchers at the Brigham and Women's Hospital and Harvard Medical School, in collaboration with the Health Campus Göttingen in Germany, contradict previous notions about sugar's role in the onset of diabetic cataracts, according to a University Medical Center G&
- Ciliatech Raises Money to Advance Development of Disruptive Glaucoma Implanthttps://modernod.com/news/ciliatech-raises-money-to-advance-development-of-disruptive-glaucoma-implant/2481560/Ciliatech announced it has raised €3.5M (about $4 million) to advance the company's glaucoma implant, CID (Cilio-scleral Inter-positioning Device), a technology that aims to disrupt traditional approaches in glaucoma surgery. Ciliatech says CID differs from other glau
- Startup Vedere Bio II Shuts Down After Preclinical Studies Fall Shorthttps://modernod.com/news/startup-vedere-bio-ii-shuts-down-after-preclinical-studies-fall-short/2481512/About 2 years after its launch, gene therapy start-up Vedere Bio II is shutting down. The decision comes after preclinical studies did not meet targets. The announcement was made from the company’s chairman Kevin Bitterman and CEO Cyrus Mozayeni. “We had a bold mission, to d
- Survey: Employees Value Vision Care as Much as Dental, but Many are Leaving Benefits on the Tablehttps://modernod.com/news/survey-employees-value-vision-care-as-much-as-dental-but-many-are-leaving-benefits-on-the-table/2481495/A new survey conducted by The Harris Poll for XP Health finds that employees value vision care as much as dental, but many are confused about how to take advantage of it—even when they have vision benefits. According to the